171 related articles for article (PubMed ID: 16608120)
1. A novel assay to detect low-titred antibodies to interferon beta in multiple sclerosis patients.
Di Marco P; Pagnotti P; Bellomi F; De Vito G; Sessa E; Bagnato F; Scagnolari C; Bramanti P; Antonelli G
New Microbiol; 2006 Jan; 29(1):11-8. PubMed ID: 16608120
[TBL] [Abstract][Full Text] [Related]
2. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
Deisenhammer F; Schellekens H; Bertolotto A
J Neurol; 2004 Jun; 251 Suppl 2():II31-9. PubMed ID: 15264110
[TBL] [Abstract][Full Text] [Related]
3. Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients.
Lampasona V; Rio J; Franciotta D; Furlan R; Avolio C; Fazio R; Lavolpe V; Vincent A; Comi G; Trojano M; Montalban X; Martino G
Eur Cytokine Netw; 2003; 14(3):154-7. PubMed ID: 14656689
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.
Sominanda A; Lundkvist M; Fogdell-Hahn A; Hemmer B; Hartung HP; Hillert J; Menge T; Kieseier BC
Arch Neurol; 2010 Sep; 67(9):1095-101. PubMed ID: 20837854
[TBL] [Abstract][Full Text] [Related]
5. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K;
Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing antibodies to interferon.
Noronha A
Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres.
Bellomi F; Bramanti P; Trojano M; Scagnolari C; Muto A; Sessa E; La Volpe V; Russo P; Antonelli G
J Immunoassay Immunochem; 2009; 30(1):40-50. PubMed ID: 19117201
[TBL] [Abstract][Full Text] [Related]
9. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
10. An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis.
Garg N; Weinstock-Guttman B; Bhasi K; Locke J; Ramanathan M
Mult Scler; 2007 Aug; 13(7):895-9. PubMed ID: 17468449
[TBL] [Abstract][Full Text] [Related]
11. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera.
Prince HE; Lapé-Nixon M; Audette C; Van Horn K
J Neuroimmunol; 2007 Oct; 190(1-2):165-9. PubMed ID: 17889376
[TBL] [Abstract][Full Text] [Related]
12. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system.
Shapiro AM; Jack CS; Lapierre Y; Arbour N; Bar-Or A; Antel JP
Arch Neurol; 2006 Sep; 63(9):1296-9. PubMed ID: 16966508
[TBL] [Abstract][Full Text] [Related]
13. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
[TBL] [Abstract][Full Text] [Related]
14. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K
Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
[TBL] [Abstract][Full Text] [Related]
15. Antibodies against interferon-beta in multiple sclerosis.
Aarskog NK; Marøy T; Myhr KM; Vedeler CA
J Neuroimmunol; 2009 Jul; 212(1-2):148-50. PubMed ID: 19467718
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
Massart C; Gibassier J; Oger J; Le Page E; Edan G
Clin Chim Acta; 2007 Feb; 377(1-2):185-91. PubMed ID: 17123498
[TBL] [Abstract][Full Text] [Related]
17. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
[TBL] [Abstract][Full Text] [Related]
19. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
Pachner AR; Cadavid D; Wolansky L; Skurnick J
Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
[TBL] [Abstract][Full Text] [Related]
20. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
Seres E; Vécsei L
Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
